AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 172 min read$SGMT

Kemble George sold $3.6M of SGMT

Kemble George sold 350,987 shares of Sagimet Biosciences Inc. (SGMT) at $10.23 ($3.59M total) on 2026-08-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kemble George
Published Aug 17, 2026, 8:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$SGMT
Neutral
medium confidence
Mentioned
$SGMT
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SGMTNeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 350,987 shares at $10.2328 per share, totaling $3,591,579.77, with holdings after the sale of 62,161 shares.

02

Market read

Traders may note the insider sale for sentiment/positioning, but it is unlikely to drive a fundamental repricing by itself.

03

What to watch

The filing does not disclose reasons for sale, and the net effect depends on whether other insiders are also selling or buying around the same period.

Relevance 5/10Novelty 3/10Timing: filed after-hours on 2026-08-17; transaction dated 2026-08-14

Background

The article is a SEC Form 4 insider transaction disclosure for Sagimet Biosciences (SGMT).

Company-level read

Ticker impact

$SGMTNeutralMedium confidence
Context

Sagimet Biosciences director Kemble George sold 350,987 shares in an open-market transaction worth about $3.59M under a 10b5-1 plan.

Expected impact

Likely limited, with any impact more sentiment-driven than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

No clear sector read-through; this is company-specific insider activity.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

A 10b5-1 sale can be routine liquidity planning and may not signal reduced confidence.

Key entities

  • issuer
    Sagimet Biosciences Inc.

    Subject of the Form 4 insider transaction disclosure (SGMT).

  • insider
    Kemble George

    Director who executed the open-market sale under a pre-arranged 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

SGMT insider trading history →

Related articles

AUG 13
$SGMTMedAI 8/10

Sagimet Biosciences Cleared To Begin Phase 3 Acne Trial Of Denifanstat

Sagimet Biosciences (SGMT) said it received an FDA “Study May Proceed” letter and IND clearance to start a pivotal Phase 3 trial of oral drug Denifanstat for moderate to severe acne in adolescents and adults. The randomized, double-blind, placebo-controlled study (about 800 patients) is expected to begin in 2H 2026, with 12-week treatment plus 40-week extension.

rttnews.com4 min
AUG 13
$SGMTMedAI 8/10

Sagimet Biosciences Inc.: Sagimet Biosciences Receives FDA "Study May Proceed" Letter and IND Clearance for Phase 3 Trial in Acne in Adolescent and Adult Patients

Sagimet Biosciences (Nasdaq: SGMT) said the FDA cleared its IND and issued a “Study May Proceed” letter for denifanstat, a Phase 3 FASN inhibitor for moderate to severe acne. The trial is planned to start in 2H 2026, enrolling about 800 U.S. patients (450 adolescents). Dosing is 50 mg once daily vs placebo for 12 weeks, with a 40-week open-label extension.

finanznachrichten.de4 min
AUG 12
$SGMTMedAI 8/10

Why is Sagimet Biosciences stock climbing today?

Sagimet Biosciences (SGMT) shares rose 3.4% pre-open to $9.84 after Q2 2026 results. The company reported a net loss of $14.0 million for the quarter ended June 30, slightly better than consensus, and reaffirmed its denifanstat pipeline. It cited Phase 3 data from Ascletis in China showing about a 20-point improvement vs placebo, with no serious adverse events, and plans a U.S. Phase 3 trial enrolling 800 patients starting H2 2026. Analysts rate it Strong Buy with a $28.50 average 12-month targe

investing.com4 min
AUG 11
$SGMTMed

Sagimet Biosciences Inc.: Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

Sagimet Biosciences (Nasdaq: SGMT) reported Q2 2026 results and updates. It plans to initiate a U.S. registrational Phase 3 for denifanstat in moderate to severe acne in 2H 2026. First-in-human Phase 1 for FASN inhibitor TVB-3567 is ongoing. In April 2026 it raised $175.0M gross. Cash and marketable securities were $257.6M at June 30, 2026, funding operations through 2028.

finanznachrichten.de3 min
AUG 11
$SGMTMed

Sagimet Biosciences Inc. (SGMT): Results of Operations and Financial Condition

Sagimet Biosciences Inc. (SGMT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sagimet Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates Phase 3 clinical trial of denifanstat in moderate to severe acne patients for the U.S. on track to initiate in second half of 2026 First-in-human Phase 1 clinical trial o

SEC EDGAR 8-K4 min